Varenicline Shows Gender-Specific Efficacy for Cannabis Use Disorder in Phase 2 Trial
核心洞察
A phase 2 randomized controlled trial involving 174 participants found that varenicline, a smoking cessation medication, significantly reduced cannabis use in men with cannabis use disorder (搜索) but showed no effect in women.
Men receiving varenicline averaged 7.9 cannabis sessions per week during treatment compared to over 12 sessions in the placebo group, while women showed no significant difference between treatment groups.
The study reveals important gender differences in treatment response, with women on varenicline experiencing higher withdrawal, craving, and anxiety scores along with lower medication adherence.
A phase 2 randomized controlled trial has demonstrated that varenicline, the FDA-approved smoking cessation medication marketed as Chantix/Champix, can significantly reduce cannabis use in men with cannabis use disorder (搜索) (CUD), though the treatment showed no efficacy in women. The findings, published in Addiction, represent a potential breakthrough for treating a condition that currently has no approved pharmacological interventions.
The study, conducted at the Medical University of South Carolina, enrolled 174 participants with CUD who used cannabis at least three days per week. Participants were randomized to receive either varenicline, titrated up to 1 mg twice daily, or placebo for 12 weeks, alongside weekly brief medical management sessions to encourage treatment adherence.
Gender-Specific Treatment Outcomes
The trial revealed striking differences in treatment response between men and women. Men receiving varenicline demonstrated substantial reductions in cannabis use compared to their placebo counterparts. The varenicline group averaged 7.9 cannabis sessions per week during the study period and 5.7 sessions in the week following treatment completion, compared with more than 12 weekly sessions for men on placebo.
Additionally, men on varenicline used cannabis an average of 3.8 days per week, compared with 4.7 days per week for the male placebo group. These differences represent clinically meaningful reductions in cannabis consumption patterns.
In contrast, women showed no significant treatment benefit from varenicline. The female varenicline group averaged just over 10 sessions per week, compared with the placebo group's 9.2 weekly sessions, which dropped to 8.2 in the week following the study. Women receiving varenicline used cannabis an average of 4.9 days per week, compared with 3.6 days for the female placebo group.
Adverse Effects and Adherence Challenges
The gender disparity extended beyond efficacy to tolerability profiles. Women receiving varenicline experienced higher withdrawal and craving scores compared to all other study groups, along with elevated anxiety levels. These adverse effects appeared to impact treatment compliance, as women on varenicline reported lower medication adherence than women receiving placebo.
The differential response pattern is particularly notable given that varenicline demonstrates equal efficacy as a smoking cessation aid in both men and women, suggesting unique mechanisms may be involved in cannabis use disorder (搜索) treatment.
Clinical Significance and Future Directions
Cannabis use disorder (搜索) represents a growing clinical challenge, with rising prevalence attributed partly to legalization efforts across multiple countries and U.S. states. The condition is characterized by continued cannabis use despite clinically significant impairment, including neglect of important social, occupational, or recreational activities and persistent use despite associated physical or psychological problems. Cannabis use is also linked to psychosis (搜索), sleep disorders (搜索), withdrawal symptoms, and mood and anxiety disorders (搜索).
"Cannabis use disorder (搜索) is rising quickly in the United States. Current pharmacological treatment options are very limited, and so our ability to help people reduce their cannabis use is also limited," said Professor Aimee McRae-Clark, the study's lead author from the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina.
The research team plans to expand their investigation with larger female cohorts to better understand the sex-specific treatment differences. "Our next step is to further explore varenicline for cannabis use disorder (搜索), using a larger sample size of women, to better understand this sex difference in the treatment outcome. In the meantime, we are encouraged that varenicline shows potential promise in treating this fast-growing problem," McRae-Clark added.
The study's findings open new avenues for personalized treatment approaches in cannabis use disorder (搜索), potentially offering the first pharmacological option for male patients while highlighting the need for alternative strategies for women with the condition.